Last reviewed 2026-04-20 · How we verify

Stelara

At a glance

Approved indications

• Crohn's disease
• Plaque psoriasis
• Psoriasis
• Psoriasis with arthropathy
• Ulcerative colitis

Common side effects

• Infections
• Infections (long-term follow-up)

Serious adverse events

• Malignancies (excluding non-melanoma skin cancer)
• Non-melanoma skin cancer
• Serious infections (long-term follow-up)
• Serious infections (placebo-controlled period)
• Cellulitis
• Herpes zoster
• Diverticulitis
• PRES (Posterior Reversible Encephalopathy Syndrome)

Key clinical trials

• Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
• A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab
• A Long-term Extension Study of Ustekinumab in Pediatric Participants (PHASE3)
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
• Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
• A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) (PHASE4)
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (PHASE2,PHASE3)
• A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Stelara CI brief — competitive landscape report
• Stelara updates RSS · CI watch RSS
• Biocon Biologics UK Ltd portfolio CI